Taipei Medical University

China Medical University

Yung Shin Pharmaceutical Ind. Co., Ltd.

Calgent Biotechnology Co., Ltd.

National Taiwan University

University of North Carolina at Chapel Hill

China Medical University Hospital

Changhua Christian Medical Foundation Changhua Christian Hospital

National Research Institute of Chinese Medicine, Ministry of Health and Welfare

Carlsbad Technology, Inc.

Shiow-Lin Pan

Che-Ming Teng

Sheng-Chu Kuo

Jing-Ping Liou

Jih-Hwa Guh

Kuo-Hsiung Lee

Tian-Shung Wu

Li-Jiau Huang

Li-Chen Chou

Chih-Shiang Chang

Yun Yen

Chung-Ming Sun

Jai-Sing Yang

Tzong-Der Way

Jing-Gung Chung

Shih-Ming Huang

Ching-Che Huang

Jang-Chang Lee

Chien-Ting Chen

Fang-Yu Lee

Yang-Chang Wu

Woei-Cherng Shyu

Yu-Ching Lee

Hui-po Wang

Chen-Huan Lin

Fang Yu Lee

Keng-Chang Tsai

Kai-Wei Chang

Chien Huang Lin

Min-Tsang Hsieh

Hsin-Yi Hung

Ling-Chu Chang

Po-Li Wei

Wei-Ling Chang

Chun-Li Wang

Xiaoming Yang

Chia-Ron Yang

Mei-Juan Wang

Wei-Chun Huangfu

Tsui-Chin Huang

Han-Li Huang

Chun-Chun Cheng

Cheng-Chiao Huang

Kun-Tu Yeh

Ting-Yi Sung

Fu-Ling Chang

Jang-Feng Lian

Ju-Fang Liu

Zhi-Jun Zhang

Chih-Ya Wang

Chung Y Hsu

Liu Yang

Yong-Long Zhao

Ying-Qian Liu

Masuo Goto

Keduo Qian

Yuan-Yi Wang

Jing Ping Liou

The invention relates to compounds of formula (I) with low cytotoxicity for blocking the ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of disorders including, but not limited to, cancers.

Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases

The invention relates to anti-EGF like domain multiple 6 antibody (anti-EGFL6 antibody) and cancer detection (or diagnosis) and treatment using the anti-EGFL6 antibody. The present invention creates anti-EGFL6 antibodies, particularly, a single-chain antibody fragments (scFv) and humanized antibody, which have ability in binding to EGFL6 and in inhibiting angiogenesis and cancer cell growth.

Anti-EGF like domain multiple 6 (EGFL6) antibodies

This disclosure is related to aromatic compounds of formula (I), and methods of their use in treating medical conditions associated with Heat Shock Protein-90 (HSP90), e.g., cancer. Compounds of formula (I) have the following structure: Also disclosed are pharmaceutical compositions comprising compounds of formula (I).

Heat shock protein 90 inhibitors

Disclosed is hydroxamic acid compounds of Formula (I) set forth herein. Also disclosed are a pharmaceutical composition containing such a compound and a method of using the compound for treating a condition associated with histone deacetylase 6.

Histone deacetylase 6 inhibitors and use thereof

The invention relates to the use of Indoline derivatives, and their effective dose in the prevention and/or treatment of fibrosis diseases. The compound can effectively prevent and/or treat a fibrosis disease without cytotoxicity or genotoxicity.

Indoline derivatives for treatment and/or prevention of fibrosis diseases

The invention relates to new compounds with low cytotoxicity for blocking ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of treating disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders and autoimmune disorders and metabolic disorders.

Compounds and pharmaceutical composition associated with ubiquitination-proteasome system

The invention relates to a compound of formula (I) with low cytotoxicity for blocking the ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of disorders including, but not limited to, multiple myeloma, cancers, neurodegenerative diseases, inflammatory disorders, autoimmune disorders and metabolic disorders.

The present invention is related to novel 20-sulfonylamidine derivatives of camptothecin (1), method of synthesizing the same, and use thereof as an antitumor agent, for examples an antitumor agent for treating nasopharyngeal, lung, breast or prostate cancer.

[object Object]

2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120(Naform) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and N,N-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.

2-phenyl-4-quinolones as anticancer agents

2-selenophene-4-quinolones as anticancer agents

2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120 (Naform) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and N,N-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.

Hydrophilic derivatives of 2-selenophene-4-quinolones as anticancer agents

This invention relates to piperazinedione compounds shown in the specification. These compounds are tyrosine kinase inhibitors and can be used to treat cancer.

Piperazinedione compounds

Benzimidazole compounds of formula (I): wherein R, R, R, R, R, X, Y, Z, and Zare defined herein. Also disclosed is a method for treating cancer with benzimidazole compounds.

Benzimidazole compounds and their use as anticancer agents

2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120 (Na+ form) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and &#x39b;/, &#x39b;/-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.

Hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents

Growing community of inventors

Taipei, Taiwan

Shiow-Lin Pan